MK-1942

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Alzheimer's DiseaseTreatment Resistant Depression

Phase 1

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

CompletedNCT04308304

Merck Sharp & Dohme LLCAlzheimer's Disease

Start: 2021-02-16End: 2022-05-18Updated: 2024-08-15

Phase 2

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

TerminatedNCT04663321

Merck Sharp & Dohme LLCTreatment Resistant Depression

Start: 2021-05-20End: 2023-09-08Updated: 2026-05-04

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

TerminatedNCT05602727

Merck Sharp & Dohme LLCAlzheimer's Disease

Start: 2022-12-02End: 2023-09-27Updated: 2024-12-10

Related Papers

Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression

Journal of Clinical Psychopharmacology2026-03-19